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Microbial resistance against clinical used antibiotics is on the rise. Accordingly, there is a high demand 
for new innovative antimicrobial strategies. The host-defense peptide human beta-defensin 1 (hBD-1) is 
produced continuously by epithelial cells and exhibits compelling antimicrobial activity after reduction 
of its disulphide bridges. Here we report that proteolysis of reduced hBD-1 by gastrointestinal proteases 
as well as human duodenal secretions produces an eight-amino acid carboxy-terminal fragment. the 
generated octapeptide retains antibiotic activity, yet with distinct characteristics differing from the 
full-length peptide. We modified the octapeptide by stabilizing its termini and by using non-natural 
D-amino acids. The native and modified peptide variants showed antibiotic activity against pathogenic 
as well as antibiotic-resistant microorganisms, including E. coli, P. aeruginosa and C. albicans. Moreover, 
in an in vitro C. albicans infection model the tested peptides demonstrated effective amelioration of  
C. albicans infection without showing cytotoxity on human cells. In summary, protease degradation of 
hBD-1 provides a yet unknown mechanism to broaden antimicrobial host defense, which could be used 
to develop defensin-derived therapeutic applications.
Antimicrobial peptides (AMPs) are evolutionary ancient peptide antibiotics produced by all multicellular organ-
isms. They are part of the primary defense against microbial infections and exhibit antimicrobial activity against 
bacteria, fungi and some enveloped viruses1,2. Humans produce different classes of AMPs, one of them are the 
defensins. These secreted peptides are characterized by their small size (3 to 5 kDa), cationic net charge and 
six conserved cysteine residues, which are connected via three disulphide bridges1,3,4. Human beta-defensin 
1 (hBD-1) was the first beta-defensin identified in humans and is produced by epithelia, monocytes, plasma-
cyoid dendritic cells and platelets5–8. In contrast to inducible beta-defensins 2 and 3, hBD-1 is produced con-
stitutively and its expression can be regulated by peroxisome proliferator-activated receptor gamma (PPARγ) 
and hypoxia-inducible factor alpha (HIF1-α)6,9,10. We could recently show that antimicrobial activity of hBD-1 
is strongly increased after reduction of its three disulphide bridges independent of bacterial Gram-status11,12. 
Activation of the peptide could be executed by a reducing environment or enzymatically by the oxido-reductase 
thioredoxin11,13.
Due to their ancient evolutionary origin and the strong demand for novel antimicrobial strategies, AMPs have 
been considered as potential antibiotic drug candidates. Mainly because they target “Achilles heels” of microor-
ganisms, only few resistance mechanisms have been evolved over long time14,15. Still, large-scale chemical syn-
thesis of defensins containing three native disulphide-bridges has been a challenge and rendered the production 
expensive. Accordingly, the production of smaller, but yet antibiotic, fragments of defensins without disulphide 
bridges is a promising option. We have shown previously that reduced hBD-1 can be degraded by the intestinal 
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protease trypsin16. Here, we evaluate a carboxy-terminal fragment of hBD-1 that is generated after proteolytic 
digestion by intestinal proteases. We investigate its antimicrobial activity and its potential to be exploited as a 
possible candidate for future antibiotic drug development.
Results
Degradation of reduced hBD-1 generates an antimicrobial octapeptide. Reduction of the three 
disulphide bridges of hBD-1 yields a linear peptide which not only differs structurally from the oxidized form11, 
but is also more prone to proteolytic degradation by the protease trypsin16. To further analyze proteolytic sus-
ceptibility of hBD-1 (Fig. 1A) towards physiological gastro-intestinal proteases, we treated oxidized and reduced 
hBD-1 with pepsin and chymotrypsin (Fig. 1B). Similar to trypsin digestion, oxidized hBD-1 was protease resist-
ant while the reduced form was readily digested. Focusing on the degradation products we detected a fragment 
having an m/z of 893.5, corresponding to the eight carboxy-terminal amino acids of hBD-1, NH2-RGKAKCCK-
COOH (RGKAKCCK). To assess the in vivo relevance of our findings in more detail, we incubated oxidized and 
reduced hBD-1 with human duodenal secretion, which is rich in proteolytic enzymes. In agreement with our in 
vitro data, ex vivo digestion generated a fragment having an m/z of 893.5 (Fig. 1C) for reduced hBD-1 but not 
for oxidized hBD-1. While the in vivo presence of the octapeptide in the human gut remains to be proven, this 
finding supports the hypothesis that proteolytic cleavage of reduced hBD-1 could generate a novel antimicrobial 
peptide in the human intestine. To test whether antibiotic activity is retained in this degradation product we next 
analyzed antimicrobial activity of the terminal octapeptide. In a radial diffusion assay (RDA)17 we thus compared 
activity of oxidized and reduced hBD-1 with the octapeptide RGKAKCCK against selected commensal and path-
ogenic microorganisms (Fig. 1D). The octapeptide exhibited convincing activity against Bifidobacterium ado-
lescentis, Streptococcus salivarius ssp. thermophilus, Escherichia coli, Candida albicans but neglectable antibiotic 
activity against Pseudomonas aeruginosa. While RGKAKCCK and oxidized hBD-1 generated no inhibition zones 
against Bifidobacterium breve, only reduced hBD-1 inhibited its growth. As expected, however, semi-quantitative 
evaluation on a molar base (4 µg reduced hBD-1 is equivalent to 254 µM in the RDA while 1 µg of octapep-
tide is equivalent to 280 µM) revealed that activity of the isolated terminus is less potent compared with the full 
length-peptide (Fig. 1D).
We found previously that cysteine residues are crucial for antimicrobial activity of hBD-1 against E. coli 
and Bif. adolescentis11,12. We confirmed these results for the terminal octapeptide, as replacing both cysteines 
(RGKAKAAK) completely abolished activity against E. coli and C. albicans (Fig. 1E, Supplementary Fig. 1). 
However, replacing either Cys6 (RGKAKACK) or Cys7 (RGKAKCAK) by alanine resulted in strongly decreased 
activity against C. albicans, while antibiotic activity of those peptides increased against E. coli. Consequently, 
cysteine residues seem to have an important, yet different, role for the antibiotic mechanism against the tested 
fungi and bacteria.
As antimicrobial peptide activity also relies on a positive net charge18,19 we further investigated the role 
of positively charged amino acids (Fig. 1E). Despite having two cysteine residues, the variants lacking Arg1 
(AGKAKCCK, net charge +3) or Arg1 and Lys3 (AGAAKCCK, net charge +2) were completely inactive against 
both tested microorganism. Thus, antimicrobial activity of the octapeptide RGKAKCCK (net charge +4) depends 
on cysteine residues as well as a particular positive charge. Yet, as a reversed-order peptide had lower activity than 
the wild-type peptide or a scrambled version, especially against C. albicans (Fig. 1F), not only the amino acid 
composition but also its sequential order or its position seem to be involved in the peptides’ activity.
Characterization of RGKAKCCK and its modified variants. Since the discovery of antimicrobial pep-
tides there is anticipation to exploit them as antibiotic drugs20. To test the potential of our octapeptide to be 
used as a therapeutic agent, we first generated peptide variants to improve its stability. To prevent non-specific 
cleavage by amino-carboxypeptidases, we chemically stabilized its termini by amino-terminal acetylation and 
carboxy-terminal amidation (Ac-RGKAKCCK-NH2) and generated both peptides also in D-amino acid config-
uration (rGkakcck and Ac-rGkakcck-NH2, respectively).
Next, to evaluate the antibiotic activity, we tested wild-type and modified peptide variants in their ability to 
inhibit growth of (opportunistic) pathogenic microorganisms (Fig. 2A). Direct comparison revealed that those 
variants with stabilized termini had promising activity against E. coli and C. albicans. Moreover, while all peptides 
displayed antimicrobial activity at pH 7.4, a reducing environment (DTT), acidification (pH 5.7), or a combina-
tion of acidification and reducing conditions (pH 5.7 + DTT) strongly decreased antimicrobial activity against 
E. coli (Supplementrary Fig. 2a) and C. albicans (Supplementrary Fig. 2b). Thus, antimicrobial acitivity of the 
generated octapeptides can be influenced by environmental conditions, in particular by reducing conditions with 
an acidic pH.
The widespread use of antibiotics in agriculture and to treat bacterial infections has led to a rapid emergence 
of microbial resistance21,22. As a consequence, in hospitals several multi-drug resistant strains exist that threaten 
effective therapy of microbial infections23. We therefore tested if the hBD1-derived peptide and its modified 
forms are also active against drug-resistant clinical isolates. As shown in Fig. 2B, we identified antimicrobial 
activity against clinical isolates of antibiotic-resistant E. coli, Pseudomonas aeruginosa and Enterococcus faecium. 
In contrast, Acinetobacter baumanii was only susceptible towards Ac-rGkakcck-NH2 whereas Enterococcus fae-
calis and K. pneumoniae were not sensitive. Direct comparison of the tested peptide revealed that the peptides 
RGKAKCCK and Ac-rGkakcck-NH2 inhibited growth of the most tested antibiotic-resistant bacteria, making 
them the most promising candidates for further drug development among the four tested peptides.
As the radial diffusion assay does not differentiate between microbistatic and microbicidal activity and con-
tains immobilized bacteria or fungal cells, we complemented our antimicrobial tests with a broth microdilution 
assay to investigate susceptibility of E. coli and C. albicans. The tested octapeptides completely inhibited C. albicans 
growth at concentrations of 100 µg/ml, while the growth of E. coli was only inhibited to 40% of the untreated 
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Figure 1. Proteolytic digestion of reduced hBD-1 generates an antimicrobial octapeptide. (A) Aminoacid 
sequence of hBD-1, depicted as one-letter code. (B) The oxidized and the reduced form of hBD-1 were digested 
with pepsin or chemotrypsin and fragments were analyzed by MALDI-MS. The carboxy-terminal fragment 
RGKAKCCK (893.5 Da, highlighted in (A) was further investigated. (C) The oxidized and the reduced hBD-1 
were digested with human duodenal secretion and fragments were analyzed by MALDI-MS. Fragments were 
identified by comparison with an in silico digest using ExPASy software. (D) Different peptide concentrations 
of oxidized (ox) and reduced (red) as well as the carboxy-terminal octapeptide RGKAKCCK were tested 
in an antimicrobial diffusion assay against several microbial strains. Diameter of inhibition zones indicates 
antimicrobial activity; a diameter of 2.5 mm (dotted line) is the diameter of an empty well. (E,F) Modifications 
of RGKAKCCK (4 µg) were tested in an antimicrobial diffusion assay against E. coli and a fungal strain C. 
albicans. Letters indicate amino acid one-letter code. All diffusion assays were carried out at least three times, 
mean +/− SEM is shown.
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control by Ac-rGkakcck-NH2 (Fig. 2C). In addition, microbial cultures were incubated with the different pep-
tides and colony forming units (CFU) were determined. For E. coli incubated with 100 µg/ml of RGKAKCCK 
or Ac-RGKAKCCK-NH2, a more than 100-fold decrease in CFU was observed when compared to untreated 
controls (Fig. 2D). In contrast, CFU reduction of C. albicans was less pronounced, thus, indicating bactericidal 
activity against E. coli and a combination of fungicidal and fungistatic activity against C. albicans of the tested 
octapeptides.
Many antimicrobial peptides target the microbial membrane24,25. To test whether this is also true for the octa-
peptides, we used a flow cytometric assay measuring membrane permeability by the dye propidium iodide (PI), 
which cannot permeate intact membranes. E. coli and C. albicans were incubated with the peptides and PI uptake, 
Figure 2. Antimicrobial activity of RGKAKCCK and its modified variants. The carboxyterminal octapeptide 
RGKAKCCK was stabilized at its termini by acetylation of the amino-terminus and amidation of the carboxy-
terminus (Ac-RGKAKCCK-NH2). Both variants were also synthesized by using D-stereoisomeric amino 
acids (indicated by small letters). Antimicrobial activity of octapeptides (4 µg) was tested against pathogenic 
microorganisms of clinical relevance (A) and with antibiotic resistance (B) in radial diffusion assay. 3-MRGN: 
multi-resistant Gram negative pathogen (3 out of 4 antibiotic classes), 4-MRGN: multi-resistant Gram 
negative pathogen (4 out of 4 antibiotic classes) MRSA: Methicillin-resistant Staphylococcus aureus, Amp/Imi: 
Ampicillin/Imipinem, Van: Vancomycin. (C) Different concentrations of octapeptides were tested in a turbidity 
liquid assay against E. coli ATCC 25922 and C. albicans ATCC 10231. Peptides were incubated with tested 
microorganisms and change in optical density (OD600nm) was measured and % growth of untreated control was 
plotted after 12 hours. (D) Aliquots were plated on agar plates and colony forming units (CFUs) were calculated 
the next day. Data are presented as mean +/− SEM of at least three independent experiments. The statistical 
significance was evaluated by using Kruskal-Wallis test compared to control and marked with *p < 0.05 and 
**p < 0.01.
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which indicated cell death, was analysed. For E. coli, all tested peptides exhibited at least 70% bacterial killing, while 
treatment with RGKAKCCK, Ac-RGKAKCCK-NH2 or Ac-rGkakcck-NH2 led to almost 100% cell death (Fig. 3A). 
In contrast, only the wild-type peptide RGKAKCCK induced up to 60% PI uptake when incubated with C. albicans.
In addition to PI uptake, we analyzed cellular membrane potential by using the membrane potential sensitive 
dye DiBAC4(3) (Fig. 3B). When incubating the peptides with E. coli, we observed strong membrane depolar-
ization for the same peptides that caused PI uptake. In contrast, C. albicans displayed less than 20% of mem-
brane depolarization. Thus, our results support a bactericidal effect of RGKAKCCK and Ac-rGkakcck-NH2 
against E. coli by targeting the bacterial membrane, while the antibiotic effect against C. albicans seems rather 
membrane-independent.
To further investigate whether octapeptide treatment leads to structural damage of the microorganisms we 
used transmission electron microscopy (TEM) to visualize peptide-treated bacteria and fungi. Incubation of 
E. coli and C. albicans with all tested variants of the octapeptide led to different degrees of structural disintegration 
(Fig. 3C). This was especially pronounced in E. coli, where all peptides caused detachment of the cell membrane 
from the cytosol, cell wall and membrane disruption as well as disintegration of cytosolic structures. In C. albicans, 
however, no destruction of the fungal cell wall could be observed, confirming results from the flow cytometric 
expriments (Fig. 3A,B). Still, disintegration of cytosolic structures could also be observed in fungal cells, similar 
to the damage observed in E. coli. Taken together, our results demonstrate a bactericidal and fungicidal/fung-
istatic effect of the tested octapeptides.
potential of the octapeptides for therapeutic drug development. For potential therapeutic applica-
tion, toxicity of the peptides needs to be excluded. We therefore analyzed cell-toxicity of all peptide variants against 
the intestinal epithelial cell line CaCo-2 and against erythrocytes. By utilization of a WST viability test we could not 
observe any cell toxicity in the relevant antimicrobial concentration ranges of 100 µg/ml (Fig. 4A) and 200 µg/ml 
(Supplementrary Fig. 4a) or any hemolytic effect against erythrocytes (Fig. 4B and Supplementrary Fig. 4b).
Figure 3. Characterization of mode of action in E. coli and C. albicans. (A) Membrane pores or (B) Membrane 
depolarization of 1 × 106 CFU E. coli ATCC 25922 or C. albicans ATCC 10231 in response to 100 µg/ml 
octapeptides were tested. Microorganisms were treated 1 h with 100 µg/ml peptide and living organisms were 
analyzed by flow cytometry. As control we used hBD3 (50 µg/ml) and Amphotericin B (20 µg/ml) and untreated 
strains. Data are presented as mean +/− SEM of at least three independent experiments. (C) Transmission 
electron microcopy of E. coli (upper panel) and C. albicans (lower panel) treated with 400 µg/ml peptide. 
Magnification bar: 0.5 µm.
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We furthermore tested the toxicity of the octapeptides by using in vitro reconstituted human oral epithelium 
(RHOE), which was analyzed by histology and lactatdehydrogenase (LDH) activity (Fig. 4C). No LDH release 
was detected with peptide variants, whereas the cytotoxic compound Triton-X-100, used as a positive control, 
induced a strong release of LDH. Similarly, when quantifying the release of the pro-inflammatory cytokines 
Interleukin-8 (IL-8) and IL-1α after incubation of the RHOE with the octapeptides we did not detect any inflam-
matory response in the RHOE (Fig. 4D).
Suitability of the octapeptides as novel candidates for antimicrobial drug development was further substan-
tiated in a model or oral candidiasis26. In this model a multilayer of RHOE was preincubated with 50 µg/ml 
(Fig. 5A) or 100 µg/ml octapeptides (Supplementrary Fig. 5) for 1 h before infecting the cells with C. albicans 
for 24 h (Fig. 5A). Epithelial damage of RHOEs was quantified by independent experts in a blinded manner on 
a scale between 0 and 5 (Fig. 5B). Untreated cells infected with C. albicans displayed evident epithelial damage 
Figure 4. Modified octapeptides are not cytotoxic. Cytotoxicity of octapeptides (100 µg/ml) was investigated 
by (A) WST-1 based test against the human intestinal epithelial cell lines CaCo-2 and (B) Hemolytic Activity 
assay against erythrocytes, using 2% Trition-X-100 and 1.25 µM Melittin as positive control. (C) Histological 
analysis of model oral epithelia treated with 100 µg/ml peptide and cytotoxicity was additionally tested by 
lactatdehydrogenase release against this model human oral epithelium. (D) Cytokine release of model oral 
epithelia was analyzed by ELISA. Mean +/− SEM of three independent experiments is shown.
7Scientific RepoRts |          (2019) 9:3640  | https://doi.org/10.1038/s41598-019-40216-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
and cell lysis and detectable fungi (coloured in red) in all layers of the epithelium. However, pre-treatment 
with RGKAKCCK convincingly reduced the fungal load in the epithelium and ameliorated epithelial dam-
age. Additionally, a histological analysis confirmed the protective effect of RGKAKCCK (Fig. 5B) whereas a 
pre-treatment with 50 µg/ml rGkakcck moderately improved epithelial damage. In contrast, epithelial dam-
age and a high amount of detectable fungal cells in lower epithelium were observed with a pre-treatment with 
the modified octapeptides Ac-RGKAKCCK-NH2 and Ac-rGkakcck-NH2: While C. albicans cells invaded the 
whole epithelium with a pre-treatment with Ac-RGKAKCCK-NH2, C. albicans invaded and damaged only the 
upper epithelium with a pre-treatment with Ac-rGkakcck-NH2. Consequently, our eight amino-acid peptide 
RGKAKCCK of the carboxy-terminus of hBD1 has the best potential to be optimized for topical application 
against infectious microbes on epithelial surfaces.
Discussion
So far, no multicellular organism has been identified which does not produce antimicrobial peptides. Even over 
a long time of evolution those host defense molecules have retained their antimicrobial capacity with only minor 
resistance mechanisms at the microbial target15,27. Thus, an improved knowledge of these antibacterial mole-
cules may help to identify novel targets for antimicrobial therapy28. In fact, in the recent years short antimicro-
bial peptides have gained increased interest as new opportunities for therapeutics29. In here, we characterized a 
carboxy-terminal octapeptide of hBD-1 that was generated after proteolytic digestion by gastro-intestinal pro-
teases and might thus occur in vivo in the human gastrointestinal tract.
Figure 5. Octapeptides are potential candidates for antimicrobial drug development. (A) Reconstituted human 
oral epithelia were pre-incubated with PBS (control uninfected) or 50 µg/ml of octapeptides as indicated. 
Subsequently cells were infected with C. albicans SC5314 (highlighted in red). Representative images are shown 
(magnification 400x, bar = 100 µm). (B) Epithelial damage was evaluated by four independent experts and the 
combined evaluation (mean +/− SEM, criteria described in methods) is shown. The statistical significance was 
evaluated by using Kruskal-Wallis test with ns = not significant and *p < 0.05.
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While reduction of disulphide bridges increases activity of several antimicrobial peptides11,30,31, it also 
increases their susceptibility towards proteolytic digestion. This is especially relevant in the intestinal tract, where 
duodenal secretions contain high amounts of proteases to facilitate digestion of dietary proteins. However, our 
observation that a degradation product of hBD-1 retains antibiotic activity indicates effective utilization of a scare 
resource: we speculate that once the reduced peptides diffuse from the intestinal mucus layer towards the lumen, 
they can be degraded as soon as they come into contact with intestinal proteases. But instead of being inactivated, 
degradation products can retain their antimicrobial activity, thereby making the most effective use of these anti-
microbial host defense molecules.
While a major shift in antimicrobial activity and activity spectrum can be observed after reduction of the 
oxidized hBD-1 (Fig. 1D, consistent with11,12,32, only minor alterations can be observed after degradation of the 
reduced peptide. However, on a molar basis the octapeptide does not exhibit the full potency of the full-length 
peptide, suggesting that the remaining 28 amino acids of hBD-1 hold additional features that enhance and mod-
ulate antibiotic activity as, for instance, observed for Bifidobacterium breve (Fig. 1D). Remarkably, and in contrast 
to hBD-1, a reducing environment diminished antimicrobial activity of the tested octapeptides against E. coli and 
C. albicans (Supplementrary Fig. 2). It is possible that due to their small size the peptides need to form dimers or 
higher-order oligomers to effectively penetrate the microbial cell wall. It is likely that such oligomerization occurs 
by forming intermolecular disulphide-bridges, thus explaining the strong dependence on cysteine residues for 
the activity of RGKAKCCK against E. coli and C. albicans (Fig. 1E). We could observe that human blood serum 
can influence bacterial growth and the antimicrobial activity (Supplementrary Fig. 3). Similarly, acidic pH led to 
lower antimicrobial activity as compared to pH 7.4 (Supplementrary Fig. 2). This is in accordance with previous 
studies, which could show that antimicrobial peptides can bind to human plasma proteins33,34. Thus, further 
optimization of a potential peptide formulation would be required to employ the octapeptide as a topical skin 
therapeutic, as human skin has a pH of about 5.5.
The cell envelope is a commonly discussed target for antimicrobial peptides35. While the full length hBD-1 
targets the bacterial cell wall and entrapped bacteria in net-like structures, the octapeptides seem to have distinct 
antimicrobial mechanisms (Fig. 2D). Our methods revealed a breakdown of membrane potential and loss of 
membrane integrity in bacteria. In contrast, treated fungal cells displayed a functional membrane but cytosolic 
defects (Fig. 3). These data highlight that our octapeptides have diverse antibiotic strategies for different micro-
organisms. Remarkably, even for the same microbial species, we observed strain specific differences in suscepti-
bility. While the P. aeruginosa ATCC type strain was not susceptible towards our octapeptides (Figs 1D and 2A), 
the multi-resistant P. aeruginosa 4-MRGN strain was susceptible (Fig. 2B). This is in accordance with previous 
studies, which could show that antibiotic-resistant bacteria show an increased sensitivity against antimicrobial 
peptides36.
Different peptides derived from β-defensins have already been investigated on their antimicrobial activity 
against bacteria and fungi37,38. For instance, 19-mer peptides derived from the carboxy-terminus of hBD-1 or 
−2 and a 22-mer derived from the terminus of hBD-3 were analyzed on their antibiotic activity. These pep-
tides retained one disulphide bridge and had lethal concentrations in the low micromolar range. With our 
carboxy-terminal octapeptide we can facilitate synthesis by significantly shortening the amino acid sequence 
and by omitting the disulphide bridge. Most studies investigating defensin-based peptides have been focused on 
hBD-3, which is one of the most potent AMPs. By generating different amino-carboxy-terminal peptides, Hoover 
et al. identified several carboxy-terminal peptides with 9 to 14 amino acids having activity against E. coli or 
P. aeruginosa, but not against S. aureus39. In these peptides, cysteine residues were replaced by serine residues, 
which we found to be also crucial for activity in our peptides. Also, Reynold et al. described that antimicrobial 
activity of hBD-3 was mainly localized in the amino-terminal half40. Similar to our results, they reported that dis-
tinct amino acids are important for activity against different strains, suggesting that the strain-selectivity of such 
peptides can be modulated by varying the sequence.
To be utilized as potential antimicrobial molecules, it has to be excluded that the generated peptides provoke 
resistance of the treated microorganism. By using a host-derived antimicrobial peptide as therapeutic, this is of 
major importance, as resistance or cross-resistance towards other AMPs might be fatal for the host. While further 
testings are required to determine whether our identified peptides provoke such resistance, we believe that the 
octapeptide can serve as a backbone structure that could be optimized to enhance and/or specialize its activity 
and to diverge from its natural structure, which would decrease the risk of resistance induction. For example, 
due to their difference in activity against E. coli and C. albicans, optimization of the peptides RGKAKACK and 
RGKAKCAK (Fig. 1E) could generate a peptide that is effective against E. coli, but not against C. albicans.
In conclusion, we identified that the host can broaden its antimicrobial arsenal by generating several antibiotic 
molecules from the AMP hBD-1, depending on its redox state and proteolytic degradation. We believe that this 
strategy can be therapeutically exploited and that our identified hBD-1 derived carboxy-terminal peptides can be 
optimized for topical application against bacterial or fungal infections.
Materials and Methods
Bacterial and fungal strains. Bacterial strains (Bifidobacterium adolescentis Ni,29c (clinical isolate), 
Bifidobacterium breve (from probiotic VSL#3) and Streptococcous salivarius ssp. thermophiles DSM 20617 were 
obtained from Ardeypharm (Germany). Escherichia coli ATCC 25922, Escherichia coli K12, Pseudomonas 
aeruginosa ATCC 27853, Candida albicans ATCC 10231, Enterococcus faecalis ATCC 29212 as well as antibi-
otic-resistant clinical isolates of Acinetobacter baumannii, Enterococcus faecalis, Enterococcus faecium, Klebsiella 
pneumoniae, Escherichia coli, Staphylococcus aureus and Pseudomonas aeruginosa were provided by the 
Department for Laboratory Medicine at Robert-Bosch-Hospital Stuttgart, Germany. Candida albicans SC5314 
was obtained from Salomé LeibundGut-Landmann (Institute of Immunology, Vetsuisse Faculty, University of 
Zürich, Switzerland).
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peptides. Carboxy-terminal octapeptides were chemically synthesized by EMC Microcollections (Tuebingen, 
Germany) and purified by precipitation. The oxidized peptides were obtained from Peptide Institute (Japan). All 
peptides were dissolved in 0.01% acetic acid.
Protease digestion and Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). 
2 µg of oxidized or reduced hBD-1 were digested with pepsin or chymotrypsin at a protease: peptide ratio of 1:20 in 
HCl-acidified water, pH 3 (pepsin) or 10 mM sodium phosphate, pH 7.4 (chymotrypsin) for 90 min. Human duode-
nal secretion (pH 6.5–7) was taken during a routine gastroscopy by rinsing the duodenum with saline. Oxidized and 
reduced hBD-1 were incubated with human duodenal secretion for 30 min at 37 °C. As a control both peptides were 
incubated with 0.9% NaCl. Peptides were enriched with ZipTip (Millipore), co-crystallized with a-cyano-4-hydroxy 
cinnamic acid and analyzed with an ultraflex TOF/TOF machine (Bruker, Germany).
Radial diffusion assay. Antimicrobial radial diffusion assay was modified from reference17 and performed 
as described earlier11. Briefly, microorganisms were cultivated (anaerobic bacteria with AnaeroGen, Oxoid, UK) 
for up to 18 hours in liquid TSB medium. Log-phase cultures were washed and diluted to 4 × 106 colony forming 
units in 10 ml agar. Incubation was carried out in 10 ml of 10 mM sodium phosphate, either pH 7.4 or 5.7, con-
taining 0.3 mg/ml of TSB powder and 1% (w/v) low EEO-agarose (AppliChem) with 0 or 1 mM dithiothreitol 
(DTT, Sigma-Aldrich) under anaerobic or aerobic conditions for three hours. 1 or 4 µg of synthetic, oxidized 
hBD-1 (Peptide Institute, Japan) and 1 or 4 µg of synthetic peptides (EMC Microcollections, Tuebingen) were 
filled into small punched wells in a final volume of 4 µl. This concentrated peptide solution dilutes while diffusing 
into the gel, thereby generating concentration-dependent, round-shaped inhibition zones when killing immobi-
lized microorganisms.
An overlay-gel containing 6% (w/v) TSB powder, 1% agarose and 10 mM sodium phosphate buffer without 
DTT was poured onto the plates and after incubation for up to 48 h at 37 °C the diameter of inhibition zones was 
measured. Experiments were repeated at least three times; mean + SEM is shown.
Microdilution broth assay. To differentiate between microbistatic and microbicidal activity we performed 
a broth microdilution assay. For that, E. coli ATCC25922 bacteria were incubated overnight at 37 °C, 150 rpm. 
C. albicans ATCC 10231 was grown at 30 °C overnight, 150 rpm in liquid TSB. Cells were collected by centrifuga-
tion (2500 rpm, 10 min, 4 °C), washed twice and resuspended in 10 mM sodium phosphate buffer containing 1% 
(w/v) TSB broth. Required C. albicans cell density was adjusted using a hemocytometer. For bacteria the optical 
density of OD600nm = 0.1 was determined. Approximately 5 × 105 CFU/ml bacteria or fungi were mixed with 
indicated peptide concentrations (1.25–200 µg/ml) in a final volume of 100 µl in 10 mM sodium phosphate buffer 
containing 1% (w/v) TSB broth and incubated for 2 hours at 37 °C. After incubation 10 µl per well were plated on 
LB-/ or YPD-agar plates to determine the CFU/ml. After that 100 µl of 6% TSB (w/v) were added and absorbance 
was measured at 600 nm (Tecan, Switzerland) and monitored for 18 hours. Growth relative to the positive control 
in % was plotted against peptide concentration. Experiments were carried out at least three times; mean ± SEM 
is shown.
Flow cytometry assay. Approximately 1.5 × 106 CFU log-phase bacteria or overnight cultured C. albicans 
ATCC 10231 were used in a final volume of 100 µl TSB (1:6 diluted H2O). We added peptides in concentra-
tions 50 and 100 µg/ml in a final volume of 10 µl and incubated theses suspensions for 1 h at 37 °C. Subsequently 
2 µl of membrane potential sensitive dye DiBAC4(3) [bis-[1,3-dibutylbarituric acid)trimethine oxonol] (Thermo 
Scientific, USA) (50 µg/ml) or Propidium Iodide (Thermo Scientific, USA) (50 µg/ml) were added and incubated 
for 10 min at room temperature. Then samples were centrifuged (5 min, 7000 rpm, RT) and re-suspended in 300 µl 
PBS. The percentage of fluorescent positive cells was determined using Canto II flow cytometer (BD Bioscience) 
with DIVA software (BD Bioscience) as described earlier41. Experiments were repeated at least three times and 
mean +/− SEM is shown.
transmission electron microscopy. Approximately 1 × 108 CFU of E. coli ATCC 25922 and C. albicans 
ATCC 10231 were incubated with 400 µg/ml peptides or control solution for 2 hours at 37 °C. Treated microor-
ganism were fixed with Karnovsky’s fixative (3% Paraformaldehyd, 3.6% Glutaraldehyd, pH 7,2) and embedded 
in 3.5% agarose at 37 °C, coagulated at room temperature, and fixed again in Karnovsky’s fixative. Post-fixed 
samples (1% OsO4, 1 h) were rinsed with distilled water, block-stained with uranyl acetate (2% in distilled water), 
dehydrated in alcohol (stepwise 30–96%), immersed in propylene oxide and embedded in glycine ether (polym-
erized 48 h at 60 C, Serva, Heidelberg). Ultra-thin sections were examined with a LIBRA 120 (Carl Zeiss AG, 
Oberkochen) at 120 kV.
Metabolic activity Assay. To assess the metobalic activity of Caco-2 cells we used the WST-1 Cell 
Proliferation Reagent (Roche, Germany). Briefly, 1 × 105 Cells /ml were seeded and incubated with 100 µg/ml or 
200 µg/ml octapeptides for 24 h at 37 °C, 5% CO2. After incubation the supernatant was removed and cells were 
washed with PBS and incubated with 20 µl Cell Proliferation Reagent WST-1 for 1 h 37 °C, 5% CO2. Finally the 
absorbance was measured at 450 nm and 620 nm. Experiments were repeated three times, mean+/− SEM.
Hemolytic Activity of antimicrobial peptides. An hemolytic activity assay for testing antimicrobial 
peptides was performed as described earlier42. Briefly, 150 µl of melittin (5 µM) was added to the positive control 
wells and incubated overnight. On the next day 1 ml blood was added to 3 ml PBS, mixed gently and centrifuged 
for 8 min, 700 × g. The supernatant was discarded and cells were re-suspended in 4 ml PBS and centrifuged again. 
After removing the supernatant, cells were centrifuged for 8 min at 1000 × g. Supernatant was discarded. For 
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each well we used 75 µl of 1% Red blood cell (RBC) suspension in PBS. RBC suspension was mixed with indi-
cated peptide concentration (2.5–200 µg/ml) in a final volume of 150 µl and incubated for 1 h at 37 °C. Finally the 
plate was centrifuged at 1000 × g for 10 min and 60 µl of supernatant was quickly transferred into a new plate. 
The absorbance was measured by 405 nm and 540 nm. Hemolytic activity was plotted relative to the 0.2% Triton 
X-100. Experiments were repeated three times; mean +/− SEM is shown.
Culture of a model human oral epithelium. 1 × 106 TR146 cells (derived from a squamous cell carcinoma 
of the buccal mucosa; SkinEthic, France) were seeded into polycarbonate plastic inserts (Millipore) in DMEM 
(Lonza) and cultured for 8 days to form a multilayered epithelium. Medium in the wells (basal) and in the inserts 
(apical) was changed daily. On day 5 (airlift) medium was aspired from the apical side and cells were fed from the 
basal side for the rest of culture time in 6-well-plates. No antibiotics were used for the entire time of culture and 
the experiments43. The octapeptides were diluted to 100 µg/ml in 0.01% acetic acid and 50 µl of these dilutions 
were applied to the apical side of the model epithelia and incubated for 24 h. The supernatant was used for cyto-
toxicity assays and Enzyme-linked immunosorbent assay.
LDH-Cytotoxicity Assay. To analyze the damage of the epithelial cells caused by octapeptides, release of 
lactate dehydrogenase (LDH) into the supernatant of RHOEs was quantified, using the cytotoxicity detection kit 
with L-LDH solution as standard, according to the manufacturer’s instructions (Roche, Germany). Supernatants 
of RHOEs were analyzed 24 h post infection.
enzyme-linked immunosorbent assay. Interleukin 8 (IL8) and IL1α were quantified in the supernatants 
of RHOEs using DuoSet ELISA-Kits (RnD Systems, US) according to the manufacturer’s instructions. Further 
details are explained above (Culture of a model human oral epithelium).
Infection of model human oral epithelium with C. albicans. Octapeptides were diluted to 50 µg/ml 
in PBS, or an equivalent volume of 0.01% acetic acid were applied to the apical side of the RHOEs and incubated 
for 1 h. C. albicans SC5314 was synchronized as described previously26. Yeast cells were washed three times in 
PBS and 1 × 105 CFU were used for infection of pre-treated RHEs. After 24 h RHEs were fixed with Karnovsky’s 
fixative. Post-fixed samples (1% OsO4, 1 h) were rinsed with distilled water, block-stained with uranyl acetate 
(2% in distilled water), dehydrated in alcohol (stepwise 30–96%), immersed in propylene oxide and embedded 
in glycide ether (polymerized 48 h at 60 °C, Serva, Heidelberg). Semi-thin sections were stained with toluidine 
blue and examined with a Nikon Eclipse 80i light microscope (magnification 1:400). Afterwards, fungal cells were 
simply coloured in red. Epithelial damage was evaluated by two independent experts in a blinded manner on a 
scale between 0 and 5 with 0 = intact epithelia, 1 = damage only in topmost cell layer; 2 = damage in top third of 
epithelium; 3 = damage in top half of epithelium; 4 = damage in all cell layers except lowermost; 5 = damage in 
all epithelial layers.
ethics statement. The study protocol was previously approved by the Ethical Committee of the University 
Hospital, Tuebingen, Germany. Patients and controls who were included in this study all gave their written and 
informed consent after the study purpose, samples procedure, and potential adjunctive risks were explained. All 
experiments were conducted in accordance with the relevant guidelines and regulations.
statistical analysis. Results are presented as mean +/− SEM from at least three independent experiments. 
Statistical analysis was performed using GraphPad Prism 7.03. The Data were not normally distributed and a 
Kruskal-Wallis test was performed. *Indicate statistically signifant differences compared to infected control. 
P-values, showing the statistical significance, were displayed by asterisks: p > 0.05 = ns; *p ≤ 0.05; **p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001.
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